News
AMPH
24.96
+2.63%
0.64
Weekly Report: what happened at AMPH last week (0914-0918)?
Weekly Report · 3d ago
3 Russell 2000 Stocks We Find Risky
Barchart · 3d ago
Amphastar Pharmaceuticals (AMPH) Could Be 4% Above Fair Value After Its Q2 Beat
Simply Wall St · 5d ago
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Seeking Alpha · 6d ago
Weekly Report: what happened at AMPH last week (0907-0911)?
Weekly Report · 09/14 09:57
Weekly Report: what happened at AMPH last week (0831-0904)?
Weekly Report · 09/07 09:52
Is Amphastar Pharmaceuticals (AMPH) Cheap After Its Recent Share Price Rebound?
Simply Wall St · 09/05 10:20
Wells Fargo Sticks to Their Hold Rating for Amphastar Pharmaceuticals (AMPH)
TipRanks · 09/02 15:05
3 Healthcare Stocks We Keep Off Our Radar
Barchart · 09/01 06:42
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
NASDAQ · 08/31 15:10
Weekly Report: what happened at AMPH last week (0824-0828)?
Weekly Report · 08/31 09:57
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
NASDAQ · 08/27 17:06
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/24 21:06
Weekly Report: what happened at AMPH last week (0817-0821)?
Weekly Report · 08/24 09:58
Amphastar Pharmaceuticals Earnings Call Balances Growth And Risk
TipRanks · 08/21 00:19
Amphastar Pharmaceuticals Is Maintained at Equal-Weight by Barclays
Dow Jones · 08/18 18:10
Amphastar Pharmaceuticals Price Target Raised to $23.00/Share From $20.00 by Barclays
Dow Jones · 08/18 18:10
Amphastar price target raised to $23 from $20 at Barclays
TipRanks · 08/18 15:15
Weekly Report: what happened at AMPH last week (0810-0814)?
Weekly Report · 08/17 09:58
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals
Simply Wall St · 08/14 10:42
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.